The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
AINU is set to accelerate its expansion footprint, enhance operational capabilities
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
